Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: Case report

International Journal of Biological Markers

Volumn 30, Issue 2, 2015, Pages e254-e257

  Campos Gomez, Saul ^a,b   Lara Guerra, Humberto ^c   Routbort, Mark J ^c   Lu, Xinyan ^c   Simon, George R ^c  

^a ISSEMYM   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

EML4 ALK; KRAS mutations; Non small cell lung cancer

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CRIZOTINIB; THYROID TRANSCRIPTION FACTOR 1; ANAPLASTIC LYMPHOMA KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; RAS PROTEIN;

ADULT; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DNA POLYMORPHISM; DRUG WITHDRAWAL; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KRAS GENE; LEG SWELLING; LUNG ADENOCARCINOMA; MIDDLE AGED; PLEURA EFFUSION; THORACOTOMY; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; GENE TRANSLOCATION; GENETICS; LUNG NEOPLASMS; MUTATION;

ECHINODERMATA;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 84934757249     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000127     Document Type: Article

References (28)

1. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6): 1190-1203.
2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448(7153): 561-566.
3. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008; 14(13): 4275-4283.
4. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4- ALK-positive lung cancer. Proc Natl Acad Sci USA. 2008; 105(50): 19893-19897.
5. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27(26): 4247-4253.
6. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008; 3(1): 13-17.
7. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008; 14(13): 4275-4283.
8. Tiseo M, Gelsomino F, Boggiani D, et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer. 2011; 71(2): 241-243.
9. Subramanian J, Govindan R. Lung cancer in 'Never-smokers': a unique entity. Oncology (Williston Park). 2010; 24(1): 29-35.
10. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers: a different disease. Nat Rev Cancer. 2007; 7(10): 778-790.
11. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011; 17(8): 2081-2086.
12. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27(26): 4247-4253.
13. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009; 15(16): 5216-5223.
14. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001; 92(6): 1525-1530.
15. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005; 92(1): 131-139.
16. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007; 25(33): 5240- 5247.
17. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008; 14(18): 5731-5734.
18. Janakiraman M, Vakiani E, Zeng Z, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 2010; 70(14): 5901-5911.
19. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol. 2009; 4(1): 5-11.
20. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007; 104(52): 20932-20937.
21. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005; 65(4): 1479-1488.
22. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003; 63(19): 6272-6281.
23. de Aguirre I, Salvatierra A, Font A, et al. c-Met mutational analysis in the sema and juxtamembrane domains in small-cell lung cancer. Transl Oncogenomics. 2006; 1(1): 11-18.
24. Goshima Y, Ito T, Sasaki Y, Nakamura F. Semaphorins as signals for cell repulsion and invasion. J Clin Invest. 2002; 109(8): 993-998.
25. Kagoshima M, Ito T. Diverse gene expression and function of semaphorins in developing lung: positive and negative regulatory roles of semaphorins in lung branching morphogenesis. Genes Cells. 2001; 6(6): 559-571.
26. Roche J, Boldog F, Robinson M, et al. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene. 1996; 12(6): 1289-1297.
27. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370(13): 1189- 1197.
28. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013; 501(7467): 355-364.